Cephalon's Treanda could become new standard in newly diagnosed non-Hodgkin's lymphoma
This article was originally published in Scrip
Executive Summary
Cephalon's new chemotherapy drug Treanda (bendamustine) has the potential to become a new standard first-line treatment for indolent non-Hodgkin's lymphoma (NHL) in combination with rituximab, according to experts presenting data from an independent, investigator-sponsored Phase III trial at the American Society of Hematology (ASH) meeting in New Orleans.